Publications

• Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma.
  Am J Hematol Volume: 100 Page(s): 548 - 551
  04/01/2025 Authors: Richter J; Dhodapkar MV; Li M; Awad M; Hampp C; Knorr K; Kroog G; Roccia T; Bumma N
• Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
  Nat Commun Volume: 16 Page(s): 2324
  03/08/2025 Authors: Shu C; Li J; Rui J; Fan D; Niu Q; Bai R; Cicka D; Doyle S; Wahafu A; Zheng X
• Smoldering multiple myeloma: Integrating biology and risk into management.
  Semin Hematol Volume: 62 Page(s): 3 - 10
  02/01/2025 Authors: Patel R; Hill E; Dhodapkar M
• Location, location, location: EMD in MM.
  Blood Volume: 144 Page(s): 2070 - 2071
  11/14/2024 Authors: Dhodapkar MV
• Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
  NPJ Vaccines Volume: 9 Page(s): 201
  10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC
• Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.
  Nat Cancer Volume: 5 Page(s): 1459 - 1464
  10/01/2024 Authors: Richard S; Lesokhin AM; Paul B; Kaufman JL; Pianko M; Biran N; Vij R; Doxie DB; Azeem MI; Martillo M
• Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
  Blood Cancer J Volume: 14 Page(s): 159
  09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S
• SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
  Clin Infect Dis Volume: 79 Page(s): 542 - 554
  08/16/2024 Authors: Hill JA; Martens MJ; Young J-AH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R
• Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
  J Clin Oncol Volume: 42 Page(s): 2702 - 2712
  08/01/2024 Authors: Bumma N; Richter J; Jagannath S; Lee HC; Hoffman JE; Suvannasankha A; Zonder JA; Shah MR; Lentzsch S; Baz R
• Understanding CAR-T therapy in myeloma: 1 cell at a time.
  Blood Adv Volume: 8 Page(s): 3560 - 3561
  07/09/2024 Authors: Dhodapkar MV
• Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA.
  Lancet Haematol Volume: 11 Page(s): e510 - e520
  07/01/2024 Authors: Khan MK; Nasti TH; Qian JY; Kleber TJ; Switchenko JM; Kaufman JL; Nooka AJ; Dhodapkar MV; Buchwald ZS; Obiekwe D
• Immune status and selection of patients for immunotherapy in myeloma: a proposal.
  Blood Adv Volume: 8 Page(s): 2424 - 2432
  05/28/2024 Authors: Dhodapkar MV
• Tregs protect against combination checkpoint blockade toxicity induced by Tph and B cell interactions.
  J Clin Invest Volume: 134
  05/02/2024 Authors: Duffy A; Azeem MI; Kanangat S; Yushak M; Lawson D; Dhodapkar MV; Dhodapkar KM
• Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
  Blood Cancer Discov Volume: 5 Page(s): 146 - 152
  05/01/2024 Authors: Ghobrial IM; Gormley N; Kumar SK; Mateos M-V; Bergsagel PL; Chesi M; Dhodapkar MV; Dispenzieri A; Fonseca R; Getz G
• TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies.
  Sci Immunol Volume: 9 Page(s): eadg1094
  04/19/2024 Authors: Minnie SA; Waltner OG; Zhang P; Takahashi S; Nemychenkov NS; Ensbey KS; Schmidt CR; Legg SRW; Comstock M; Boiko JR
• Immune-Pathogenesis of Myeloma.
  Hematol Oncol Clin North Am Volume: 38 Page(s): 281 - 291
  04/01/2024 Authors: Dhodapkar MV
• Role of Natural Killer T (NKT) Cells in Myeloma Biology and Therapy.
  Crit Rev Oncog Volume: 29 Page(s): 63 - 68
  01/01/2024 Authors: Dhodapkar MV
• Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
  Blood Cancer J Volume: 13 Page(s): 191
  12/20/2023 Authors: Scott SA; Marin EM; Maples KT; Joseph NS; Hofmeister CC; Gupta VA; Dhodapkar MV; Kaufman JL; Lonial S; Nooka AK
• BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
  NPJ Vaccines Volume: 8 Page(s): 179
  11/21/2023 Authors: Valanparambil RM; Lai L; Johns MA; Davis-Gardner M; Linderman SL; McPherson TO; Chang A; Akhtar A; Gamarra ELB; Matia H
• Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers.
  iScience Volume: 26 Page(s): 108256
  11/17/2023 Authors: Cheedarla N; Verkerke HP; Potlapalli S; McLendon KB; Patel A; Frank F; O'Sick WH; Cheedarla S; Baugh TJ; Damhorst GL
• Harnessing Dendritic Cells: Next Frontier for Durable Immune Control in Myeloma.
  Clin Cancer Res Volume: 29 Page(s): 4524 - 4526
  11/14/2023 Authors: Dhodapkar MV
• Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity.
  Nature Volume: 623 Page(s): 1034 - 1043
  11/01/2023 Authors: Fan H; Xia S; Xiang J; Li Y; Ross MO; Lim SA; Yang F; Tu J; Xie L; Dougherty U
• Role of B cells in immune-related adverse events following checkpoint blockade.
  Immunol Rev Volume: 318 Page(s): 89 - 95
  09/01/2023 Authors: Dhodapkar KM; Duffy A; Dhodapkar MV
• Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
  JCO Oncol Pract Volume: 19 Page(s): 793 - 798
  09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK
• Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
  J Clin Invest Volume: 133
  08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S
• Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies.
  Blood Adv Volume: 7 Page(s): 2459 - 2462
  06/13/2023 Authors: Chang A; Koff JL; Lai L; Orellana-Noia VM; Surati M; Leal AMK; Ellis ML; Wali B; Moreno A; Linderman SL
• Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
  Clin Lymphoma Myeloma Leuk Volume: 23 Page(s): 413 - 419
  06/01/2023 Authors: Terpos E; Neri P; van de Donk NWCJ; D'Agostino M; Parekh S; Jagannath S; Ludwig H; Avigan DE; Dhodapkar MV; Raje NS
• SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study.
  EClinicalMedicine Volume: 59 Page(s): 101983
  05/01/2023 Authors: Hill JA; Martens MJ; Young J-AH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R
• BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
  J Immunother Cancer Volume: 11
  05/01/2023 Authors: Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S
• The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.
  Am J Hematol Volume: 98 Suppl 2 Page(s): S4 - S12
  03/01/2023 Authors: Dhodapkar MV
• Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
  Blood Cancer Discov Volume: 4 Page(s): 106 - 117
  03/01/2023 Authors: Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB
• Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
  Blood Cancer J Volume: 13 Page(s): 29
  02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S
• Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma.
  NPJ Genom Med Volume: 8 Page(s): 3
  01/26/2023 Authors: Pilcher W; Thomas BE; Bhasin SS; Jayasinghe RG; Yao L; Gonzalez-Kozlova E; Dasari S; Kim-Schulze S; Rahman A; Patton J
• Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
  Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
  12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA
• Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
  J Clin Oncol Volume: 40 Page(s): 3808 - 3816
  11/20/2022 Authors: Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH
• Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
  Blood Cancer Discov Volume: 3 Page(s): 490 - 501
  11/02/2022 Authors: Dhodapkar KM; Cohen AD; Kaushal A; Garfall AL; Manalo RJ; Carr AR; McCachren SS; Stadtmauer EA; Lacey SF; Melenhorst JJ
• A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
  Clin Lung Cancer Volume: 23 Page(s): e400 - e404
  11/01/2022 Authors: Osta BE; Carlisle J; Steuer C; Pakkala S; Leal T; Dhodapkar M; Liu Y; Chen Z; Owonikoko T; Ramalingam S
• CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S281 - S282
  10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
• MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma.
  Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S406 - S407
  10/01/2022 Authors: Zonder JA; Richter J; Bumma N; Brayer J; Hoffman JE; Bensinger WI; Wu KL; Xu L; Chokshi D; Boyapati A
• Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis.
  Cancer Res Commun Volume: 2 Page(s): 1255 - 1265
  10/01/2022 Authors: Yao L; Jayasinghe RG; Lee BH; Bhasin SS; Pilcher W; Doxie DB; Gonzalez-Kozlova E; Dasari S; Fiala MA; Pita-Juarez Y
• Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
  J Clin Oncol Volume: 40 Page(s): 3020 - 3031
  09/10/2022 Authors: Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM
• Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
  J Clin Oncol Volume: 40 Page(s): 3057 - 3064
  09/10/2022 Authors: Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S
• Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC).
  J Immunother Cancer Volume: 10
  09/01/2022 Authors: Atkins MB; Abu-Sbeih H; Ascierto PA; Bishop MR; Chen DS; Dhodapkar M; Emens LA; Ernstoff MS; Ferris RL; Greten TF
• Venetoclax ex vivo functional profiling predicts improved progression-free survival.
  Blood Cancer J Volume: 12 Page(s): 115
  08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT
• Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
  Lancet Haematol Volume: 9 Page(s): e403 - e414
  06/01/2022 Authors: Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksa M; Legie W; Liberati AM; Goldschmidt H; Belch A
• Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies.
  Open Forum Infect Dis Volume: 9 Page(s): ofac171
  06/01/2022 Authors: Figueiredo JC; Hirsch FR; Kushi LH; Nembhard WN; Crawford JM; Mantis N; Finster L; Merin NM; Merchant A; Reckamp KL
• It takes T to tango: immunotherapy in MM.
  Blood Volume: 139 Page(s): 1259 - 1260
  03/03/2022 Authors: Gupta VA; Dhodapkar MV
• Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against native-like vaccine and delta variant spike trimers.
  Res Sq
  02/16/2022 Authors: Cheedarla N; Verkerke HP; Potlapalli S; McLendon KB; Patel A; Frank F; Damhorst GL; Wu H; O'Sick WH; Graciaa D
• Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
  Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
  02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT
• Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
  Leukemia Volume: 36 Page(s): 591 - 595
  02/01/2022 Authors: Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP
• How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.
  Blood Cancer Discov Volume: 2 Page(s): 562 - 567
  11/01/2021 Authors: Ribas A; Dhodapkar MV; Campbell KM; Davies FE; Gore SD; Levy R; Greenberger LM
• Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
  Blood Cancer Discov Volume: 2 Page(s): 600 - 615
  11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC
• Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.
  Leukemia Volume: 35 Page(s): 3319 - 3323
  11/01/2021 Authors: Verma R; Branagan AR; Xu ML; Flavell RA; Dhodapkar KM; Dhodapkar MV
• Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
  Blood Volume: 137 Page(s): 3604 - 3615
  07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT
• Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias.
  Blood Adv Volume: 5 Page(s): 1535 - 1539
  03/09/2021 Authors: Branagan AR; Duffy E; Gan G; Li F; Foster C; Verma R; Zhang L; Parker TL; Seropian S; Cooper DL
• Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
  Am J Hematol Volume: 96 Page(s): E68 - E71
  03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH
• Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19.
  Blood Cancer Discov Volume: 2 Page(s): 9 - 12
  01/01/2021 Authors: Dhodapkar MV; Dhodapkar KM; Ahmed R
• Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention.
  Front Immunol Volume: 12 Page(s): 632564
  01/01/2021 Authors: McCachren SS; Dhodapkar KM; Dhodapkar MV
• Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
  Lancet Haematol Volume: 8 Page(s): e45 - e54
  01/01/2021 Authors: Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M
• Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
  Blood Cancer J Volume: 10 Page(s): 125
  12/14/2020 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S
• Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.
  Clin Cancer Res Volume: 26 Page(s): 5814 - 5819
  11/15/2020 Authors: Dhodapkar MV; Sexton R; Hoering A; Van Rhee F; Barlogie B; Orlowski R
• Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
  PLoS Med Volume: 17 Page(s): e1003323
  11/01/2020 Authors: Danziger SA; McConnell M; Gockley J; Young MH; Rosenthal A; Schmitz F; Reiss DJ; Farmer P; Alapat DV; Singh A
• Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
  Biol Blood Marrow Transplant Volume: 26 Page(s): e247 - e255
  10/01/2020 Authors: Holstein SA; Howard A; Avigan D; Bhutani M; Cohen AD; Costa LJ; Dhodapkar MV; Gay F; Gormley N; Green DJ
• Risk-associated alterations in marrow T cells in pediatric leukemia.
  JCI Insight Volume: 5
  08/20/2020 Authors: Bailur JK; McCachren SS; Pendleton K; Vasquez JC; Lim HS; Duffy A; Doxie DB; Kaushal A; Foster C; DeRyckere D
• Smoldering Myeloma and the Art of War.
  J Clin Oncol Volume: 38 Page(s): 2363 - 2365
  07/20/2020 Authors: Lonial S; Dhodapkar MV; Rajkumar SV
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
  J Immunother Cancer Volume: 8
  07/01/2020 Authors: Shah N; Aiello J; Avigan DE; Berdeja JG; Borrello IM; Chari A; Cohen AD; Ganapathi K; Gray L; Green D
• Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
  JCI Insight Volume: 5
  06/18/2020 Authors: Bar N; Costa F; Das R; Duffy A; Samur M; McCachren S; Gettinger SN; Neparidze N; Parker TL; Bailur JK
• Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
  J Clin Oncol Volume: 38 Page(s): 1928 - 1937
  06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK
• Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
  Semin Immunol Volume: 49 Page(s): 101415
  06/01/2020 Authors: Dhodapkar MV; Dhodapkar KM
• Reply to N. Biran et al.
  J Clin Oncol Volume: 38 Page(s): 1368 - 1369
  04/20/2020 Authors: Lonial S; Dhodapkar MV; Rajkumar SV
• Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
  J Clin Oncol Volume: 38 Page(s): 1126 - 1137
  04/10/2020 Authors: Lonial S; Jacobus S; Fonseca R; Weiss M; Kumar S; Orlowski RZ; Kaufman JL; Yacoub AM; Buadi FK; O'Brien T
• How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
  Clin Cancer Res Volume: 26 Page(s): 1541 - 1554
  04/01/2020 Authors: Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
• Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy.
  Mol Genet Metab Volume: 129 Page(s): 286 - 291
  04/01/2020 Authors: Nair S; Bar N; Xu ML; Dhodapkar M; Mistry PK
• The Role of Early Intervention in High-Risk Smoldering Myeloma.
  Am Soc Clin Oncol Educ Book Volume: 40 Page(s): 1 - 9
  03/01/2020 Authors: Joseph NS; Dhodapkar MV; Lonial S
• Game of Bones: How Myeloma Manipulates Its Microenvironment.
  Front Oncol Volume: 10 Page(s): 625199
  01/01/2020 Authors: Moser-Katz T; Joseph NS; Dhodapkar MV; Lee KP; Boise LH
• Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
  Blood Cancer J Volume: 9 Page(s): 94
  11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J
• SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
  Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 537 - 544
  09/01/2019 Authors: Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
• Daratumumab in multiple myeloma.
  Cancer Volume: 125 Page(s): 2364 - 2382
  07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
• Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.
  J Clin Oncol Volume: 37 Page(s): 1228 - 1263
  05/10/2019 Authors: Mikhael J; Ismaila N; Cheung MC; Costello C; Dhodapkar MV; Kumar S; Lacy M; Lipe B; Little RF; Nikonova A
• Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
  Nat Commun Volume: 10 Page(s): 1911
  04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D
• Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
  JCI Insight Volume: 5
  04/23/2019 Authors: Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL
• Navigating the Fas lane to improved cellular therapy for cancer.
  J Clin Invest Volume: 129 Page(s): 1522 - 1523
  02/25/2019 Authors: Dhodapkar MV
• Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
  JCI Insight Volume: 4
  02/21/2019 Authors: Garfall AL; Stadtmauer EA; Hwang W-T; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV
• Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
  Cancer Volume: 125 Page(s): 416 - 423
  02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK
• Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
  Front Immunol Volume: 10 Page(s): 2385
  01/01/2019 Authors: Dhodapkar MV; Dhodapkar KM
• Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
  J Immunother Cancer Volume: 6 Page(s): 137
  12/04/2018 Authors: Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL
• African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120
  Volume: 132
  11/29/2018 Authors: Dhodapkar MV; Sexton R; Hoering A; Barlogie B; Orlowski RZ
• The contribution of cross-talk between the cell-surface proteins CD36 and CD47-TSP-1 in osteoclast formation and function.
  J Biol Chem Volume: 293 Page(s): 15055 - 15069
  09/28/2018 Authors: Koduru SV; Sun B-H; Walker JM; Zhu M; Simpson C; Dhodapkar M; Insogna KL
• Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
  Br J Haematol Volume: 182 Page(s): 495 - 503
  08/01/2018 Authors: Jagannath S; Laubach J; Wong E; Stockerl-Goldstein K; Rosenbaum C; Dhodapkar M; Jou Y-M; Lynch M; Robbins M; Shelat S
• MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association.
  Blood Volume: 131 Page(s): 2500 - 2501
  05/31/2018 Authors: Weinreb NJ; Mistry PK; Rosenbloom BE; Dhodapkar MV
• Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
  Volume: 36
  05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK
• Antigen-mediated regulation in monoclonal gammopathies and myeloma.
  JCI Insight Volume: 3
  04/19/2018 Authors: Nair S; Sng J; Boddupalli CS; Seckinger A; Chesi M; Fulciniti M; Zhang L; Rauniyar N; Lopez M; Neparidze N
• Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
  JCI Insight Volume: 3
  04/19/2018 Authors: Garfall AL; Stadtmauer EA; Hwang W-T; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV
• TWO DOSE SERIES OF HIGH-DOSE INFLUENZA VACCINE IS ASSOCIATED WITH LONGER DURATION OF SEROLOGIC IMMUNITY IN PATIENTS WITH PLASMA CELL DISORDERS
  Volume: 103 Page(s): 41 - 41
  04/18/2018 Authors: Branagan A; Duffy E; Foster C; Zhang L; Verma R; Gan G; Li F; Dhodapkar M
• Early B cell changes predict autoimmunity following combination immune checkpoint blockade.
  J Clin Invest Volume: 128 Page(s): 715 - 720
  02/01/2018 Authors: Das R; Bar N; Ferreira M; Newman AM; Zhang L; Bailur JK; Bacchiocchi A; Kluger H; Wei W; Halaban R
• Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
  Front Immunol Volume: 9 Page(s): 2204
  01/01/2018 Authors: Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
• Early Enrichment and Subsequent Dysfunction of Marrow ILC Subsets in Monoclonal Gammopathy: Target for IMiD Therapy
  Volume: 130
  12/07/2017 Authors: Bailur JK; Mehta S; Zhang L; Neparidze N; Parker TL; Bar N; Anderson T; Xu M; Dhodapkar K; Dhodapkar MV
• Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy.
  Blood Adv Volume: 1 Page(s): 2343 - 2347
  11/28/2017 Authors: Kini Bailur J; Mehta S; Zhang L; Neparidze N; Parker T; Bar N; Anderson T; Xu ML; Dhodapkar KM; Dhodapkar MV
• A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).
  Volume: 35
  05/20/2017 Authors: Cho HJ; Cole C; Martin TG; Zonder JA; Fay JW; Vij R; Byon JCH; Stewart AK; Dhodapkar MV
• Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.
  Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): 296 - 304.e2
  05/01/2017 Authors: Branagan AR; Duffy E; Albrecht RA; Cooper DL; Seropian S; Parker TL; Gan G; Li F; Zelterman D; Boddupalli CS
• Precancer Atlas to Drive Precision Prevention Trials.
  Cancer Res Volume: 77 Page(s): 1510 - 1541
  04/01/2017 Authors: Spira A; Yurgelun MB; Alexandrov L; Rao A; Bejar R; Polyak K; Giannakis M; Shilatifard A; Finn OJ; Dhodapkar M
• Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.
  Volume: 35
  03/01/2017 Authors: Dhodapkar KM; Boddupalli CS; Bar N; Kadaveru K; Krauthammer M; Pornputtapong N; Mai Z; Ariyan S; Narayan D; Kluger HM
• Type II NKT Cells and Their Emerging Role in Health and Disease.
  J Immunol Volume: 198 Page(s): 1015 - 1021
  02/01/2017 Authors: Dhodapkar MV; Kumar V
• Association of lysolipids with Gaucher disease - associated and sporadic gammopathies
  Volume: 120 Page(s): S100 - S100
  01/01/2017 Authors: Nair S; Sng J; Zhang L; Branagan A; Liu J; Boddupalli CS; Meffre E; Mistry P; Dhodapkar M
• Systematic evaluation of immune regulation and modulation.
  J Immunother Cancer Volume: 5 Page(s): 21
  01/01/2017 Authors: Stroncek DF; Butterfield LH; Cannarile MA; Dhodapkar MV; Greten TF; Grivel JC; Kaufman DR; Kong HH; Korangy F; Lee PP
• Hematologic Malignancies: Plasma Cell Disorders.
  Am Soc Clin Oncol Educ Book Volume: 37 Page(s): 561 - 568
  01/01/2017 Authors: Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
• Natural Killer T Cells in Cancer Immunotherapy.
  Front Immunol Volume: 8 Page(s): 1178
  01/01/2017 Authors: Nair S; Dhodapkar MV
• Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells.
  JCI Insight Volume: 1 Page(s): e88955
  12/22/2016 Authors: Boddupalli CS; Bar N; Kadaveru K; Krauthammer M; Pornputtapong N; Mai Z; Ariyan S; Narayan D; Kluger H; Deng Y
• MGUS to myeloma: a mysterious gammopathy of underexplored significance.
  Blood Volume: 128 Page(s): 2599 - 2606
  12/08/2016 Authors: Dhodapkar MV
• Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial
  Volume: 128
  12/02/2016 Authors: Branagan AR; Duffy E; Parker TL; Seropian S; Foster C; Zhang L; Verma R; Zelterman D; Gan G; Brandt DS
• Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice.
  Nat Med Volume: 22 Page(s): 1351 - 1357
  11/01/2016 Authors: Das R; Strowig T; Verma R; Koduru S; Hafemann A; Hopf S; Kocoglu MH; Borsotti C; Zhang L; Branagan A
• ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells.
  J Clin Invest Volume: 126 Page(s): 3905 - 3916
  10/03/2016 Authors: Boddupalli CS; Nair S; Gray SM; Nowyhed HN; Verma R; Gibson JA; Abraham C; Narayan D; Vasquez J; Hedrick CC
• Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
  J Clin Oncol Volume: 34 Page(s): 2698 - 2704
  08/10/2016 Authors: Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D
• Harnessing shared antigens and T-cell receptors in cancer: Opportunities and challenges.
  Proc Natl Acad Sci U S A Volume: 113 Page(s): 7944 - 7945
  07/19/2016 Authors: Dhodapkar K; Dhodapkar M
• A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF ELOTUZUMAB MONOTHERAPY IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA
  Volume: 101 Page(s): 328 - 329
  06/01/2016 Authors: Richardson P; Wong E; Stockerl-Goldstein K; Rosenbaum C; Dhodapkar M; Jou YM; Lynch M; Robbins M; Bleickardt E; Jagannath S
• International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
  J Clin Oncol Volume: 34 Page(s): 1544 - 1557
  05/01/2016 Authors: Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R
• Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.
  Oncoimmunology Volume: 5 Page(s): e1071008
  04/01/2016 Authors: Besse B; Charrier M; Lapierre V; Dansin E; Lantz O; Planchard D; Le Chevalier T; Livartoski A; Barlesi F; Laplanche A
• Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).
  Volume: 6 Page(s): e410
  03/25/2016 Authors: Papanikolaou X; Rosenthal A; Dhodapkar M; Epstein J; Khan R; van Rhee F; Jethava Y; Waheed S; Zangari M; Hoering A
• Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.
  N Engl J Med Volume: 374 Page(s): 555 - 561
  02/11/2016 Authors: Nair S; Branagan AR; Liu J; Boddupalli CS; Mistry PK; Dhodapkar MV
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
  J Immunother Cancer Volume: 4 Page(s): 90
  01/01/2016 Authors: Boyiadzis M; Bishop MR; Abonour R; Anderson KC; Ansell SM; Avigan D; Barbarotta L; Barrett AJ; Van Besien K; Bergsagel PL
• Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells
  Volume: 126
  12/03/2015 Authors: Verma R; Strowig T; Das R; Koduru S; Hafemann A; Hopf S; Kocoglu MH; Borsotti C; Zhang L; Branagan AR
• Fluzone (R) High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders
  Volume: 126
  12/03/2015 Authors: Branagan AR; Duffy E; Boddupall CS; Albrecht RA; Zhang L; Verma R; Cooper DL; Seropian S; Parker TL; Yao X
• Identification of a Cereblon-Independent Protein Degradation Pathway in Residual Myeloma Cells Treated with Immunomodulatory Drugs
  Volume: 126
  12/03/2015 Authors: Verma R; Mai Z; Xu M; Zhang L; Dhodapkar K; Dhodapkar MV
• Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice
  Volume: 126
  12/03/2015 Authors: Das R; Strowig T; Verma R; Koduru S; Hafemann A; Hopf S; Kocoglu MH; Borsotti C; Zhang L; Branagan AR
• Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.
  Blood Volume: 126 Page(s): 2475 - 2478
  11/26/2015 Authors: Dhodapkar MV; Sexton R; Das R; Dhodapkar KM; Zhang L; Sundaram R; Soni S; Crowley JJ; Orlowski RZ; Barlogie B
• Stem-Cell Transplantation for Amyloidosis: Improving Outcomes but Not for the Faint of Heart.
  J Clin Oncol Volume: 33 Page(s): 3689 - 3690
  11/10/2015 Authors: Bar N; Parker TL; Dhodapkar MV
• Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
  Haematologica Volume: 100 Page(s): 1214 - 1221
  09/01/2015 Authors: Khan R; Dhodapkar M; Rosenthal A; Heuck C; Papanikolaou X; Qu P; van Rhee F; Zangari M; Jethava Y; Epstein J
• Comparison of pomalidomide dosing strategies in lenalidomide-refractory myeloma: Impact on clinical outcome, immune activation and cereblon targets
  Volume: 75
  08/01/2015 Authors: Das R; Sehgai K; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M
• Immune Modulation in Hematologic Malignancies.
  Semin Oncol Volume: 42 Page(s): 617 - 625
  08/01/2015 Authors: Dhodapkar MV; Dhodapkar KM
• Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
  Volume: 75
  07/15/2015 Authors: Das R; Verma R; Sznol M; Boddupalli CS; Gettinger S; Kluger H; Dhodapkar M; Dhodapkar K
• Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
  Blood Volume: 125 Page(s): 4042 - 4051
  06/25/2015 Authors: Sehgal K; Das R; Zhang L; Verma R; Deng Y; Kocoglu M; Vasquez J; Koduru S; Ren Y; Wang M
• NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOID MALIGNANCIES AND CLASSICAL HODGKIN LYMPHOMA: UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY (CA209-039)
  Volume: 100 Page(s): 323 - 323
  06/01/2015 Authors: Armand P; Timmerman J; Lesokhin A; Halwani A; Millenson M; Schuster S; Gutierrez M; Scott E; Cattry D; Freeman G
• Consensus nomenclature for CD8+ T cell phenotypes in cancer.
  Oncoimmunology Volume: 4 Page(s): e998538
  04/01/2015 Authors: Apetoh L; Smyth MJ; Drake CG; Abastado J-P; Apte RN; Ayyoub M; Blay J-Y; Bonneville M; Butterfield LH; Caignard A
• Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation.
  Blood Volume: 125 Page(s): 1256 - 1271
  02/19/2015 Authors: Nair S; Boddupalli CS; Verma R; Liu J; Yang R; Pastores GM; Mistry PK; Dhodapkar MV
• Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
  J Immunol Volume: 194 Page(s): 950 - 959
  02/01/2015 Authors: Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV
• Conditional overexpression of TGF1 promotes pulmonary inflammation, apoptosis and mortality via TGFR2 in the developing mouse lung.
  Respir Res Volume: 16 Page(s): 4
  01/16/2015 Authors: Sureshbabu A; Syed MA; Boddupalli CS; Dhodapkar MV; Homer RJ; Minoo P; Bhandari V
• Classification of current anticancer immunotherapies.
  Oncotarget Volume: 5 Page(s): 12472 - 12508
  12/30/2014 Authors: Galluzzi L; Vacchelli E; Bravo-San Pedro J-M; Buqu A; Senovilla L; Baracco EE; Bloy N; Castoldi F; Abastado J-P; Agostinis P
• Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies
  Volume: 124
  12/06/2014 Authors: Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D
• Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt
  Volume: 124
  12/06/2014 Authors: Khan RZ; Heuck C; Rosenthal A; Stein CK; Epstein J; Yaccoby S; Papanikolaou X; Jethava Y; Zangari M; Van Rhee F
• Type II NKT-TFH Cells Against Gaucher Lipids Regulate B Cell Immunity and Inflammation
  Volume: 124
  12/06/2014 Authors: Nair S; Boddupalli CS; Verma R; Liu J; Ruhua Y; Pastores GM; Mistry P; Dhodapkar MV
• Dual Face of Immune Microenvironment in Myeloma
  Volume: 124
  12/06/2014 Authors: Dhodapkar MV
• Trial watch: Dendritic cell-based anticancer therapy.
  Oncoimmunology Volume: 3 Page(s): e963424
  11/01/2014 Authors: Bloy N; Pol J; Aranda F; Eggermont A; Cremer I; Fridman WH; Fukov J; Galon J; Tartour E; Spisek R
• Targeting human dendritic cells in situ to improve vaccines.
  Immunol Lett Volume: 162 Page(s): 59 - 67
  11/01/2014 Authors: Sehgal K; Dhodapkar KM; Dhodapkar MV
• Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk.
  J Immunol Volume: 193 Page(s): 2297 - 2305
  09/01/2014 Authors: Sehgal K; Ragheb R; Fahmy TM; Dhodapkar MV; Dhodapkar KM
• Serial exome analysis of disease progression in premalignant gammopathies.
  Leukemia Volume: 28 Page(s): 1548 - 1552
  07/01/2014 Authors: Zhao S; Choi M; Heuck C; Mane S; Barlogie B; Lifton RP; Dhodapkar MV
• Differentiating asymptomatic monoclonal gammopathy (AMG including MGUS and AMM) from clinical multiple myeloma (CMM) by gene expression profiling of purified plasma cells (PC-GEP).
  Volume: 32
  05/20/2014 Authors: Khan R; Heuck CJ; Rosenthal A; Dhodapkar MV; Miller SE; Qu P; Johann DJ; Van Rhee F; Jethava Y; Zangari M
• SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM)
  Volume: 32
  05/20/2014 Authors: Usmani SZ; Hoering A; Sexton R; Ailawadhi S; Shah JJ; Fredette S; Durle BG; Zonder JA; Dhodapkar MV; Rajkumar SV
• Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.
  Sci Transl Med Volume: 6 Page(s): 232ra51
  04/16/2014 Authors: Dhodapkar MV; Sznol M; Zhao B; Wang D; Carvajal RD; Keohan ML; Chuang E; Sanborn RE; Lutzky J; Powderly J
• Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
  Blood Volume: 123 Page(s): 78 - 85
  01/02/2014 Authors: Dhodapkar MV; Sexton R; Waheed S; Usmani S; Papanikolaou X; Nair B; Petty N; Shaughnessy JD; Hoering A; Crowley J
• Recent advances and new opportunities for targeting human dendritic cells in situ.
  Oncoimmunology Volume: 3 Page(s): e954832
  01/01/2014 Authors: Dhodapkar MV; Dhodapkar KM
• Both Intermittent and Continuous Dosing Regimens Of Pomalidomide Mediate Broad Activation Of Innate and Adaptive Immunity In Relapsed/Refractory Myeloma: Results Of A Phase II Randomized Trial
  Volume: 122
  11/15/2013 Authors: Dhodapkar K; Zhang L; Verma R; Sehgal K; Kocoglu MH; Dhodapkar MV
• Cytogenetic Features Of Patients With Monoclonal Gammopathy Of Undetermined Significance (MGUS) and Asymptomatic Multiple Myeloma (AMM)
  Volume: 122
  11/15/2013 Authors: Tian E; Waheed S; Sawyer J; Zhang Q; Heuck C; Dhodapkar MV; Barlogie B; Epstein J
• SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.
  Oncoimmunology Volume: 2 Page(s): e25205
  07/01/2013 Authors: Dhodapkar KM; Gettinger SN; Das R; Zebroski H; Dhodapkar MV
• Clinical, genomic, and imaging predictors of malignancy: Analysis of the first US cooperative group prospective clinical trial in asymptomatic monoclonal gammopathies (SWOG S0120)
  Volume: 31
  05/20/2013 Authors: Dhodapkar MV; Sexton R; Waheed S; Usmani SZ; Papanikolaou XD; Nair BP; Petty N; Shaughnessy JD; Hoering A; Crowley J
• Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right?
  Cancer Prev Res (Phila) Volume: 6 Page(s): 173 - 176
  03/01/2013 Authors: Dhodapkar MV
• Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.
  Blood Volume: 121 Page(s): 423 - 430
  01/17/2013 Authors: Richter J; Neparidze N; Zhang L; Nair S; Monesmith T; Sundaram R; Miesowicz F; Dhodapkar KM; Dhodapkar MV
• Incidence and Outcomes for Low Risk Myelodysplastic Syndrome: A Surveillance, Epidemiology and End Results (SEER) Study
  Volume: 120
  11/16/2012 Authors: Zhang Y; Podoltsev NA; Rothberg BEG; Dhodapkar MV; Morgensztern D
• Gene Expression Profiling (GEP) in MGUS and AMM: Predictors of Progression
  Volume: 120
  11/16/2012 Authors: Waheed S; Heuck C; Qu P; van Rhee F; Usmani SZ; Zhang Q; Sexton R; Crowley J; Epstein J; Dhodapkar MV
• A Phase 1 Trial of a Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 in Combination With Toll-like Receptor Agonists
  Volume: 35 Page(s): 740 - 740
  11/01/2012 Authors: Dhodapkar M; Zhao B; Wang D; Carvajal RD; Keohan M; Chuang E; Sanborn R; Lutzky J; Powderly J; Kluger H
• Induction of activation-induced cytidine deaminase (AID) by dendritic cells leads to genomic instability in human myeloma
  Volume: 72
  04/15/2012 Authors: Koduru S; Wong E; Strowig T; Sundaram R; Zhang L; Strout MP; Flavell RA; Schatz DG; Dhodapkar KM; Dhodapkar MV
• Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.
  Blood Volume: 119 Page(s): 2302 - 2309
  03/08/2012 Authors: Koduru S; Wong E; Strowig T; Sundaram R; Zhang L; Strout MP; Flavell RA; Schatz DG; Dhodapkar KM; Dhodapkar MV
• Adipokines in MM: time to trim the fat.
  Blood Volume: 118 Page(s): 5716 - 5717
  11/24/2011 Authors: Dhodapkar MV
• SWOG S0120 Observational Trial for MGUS and Asymptomatic Multiple Myeloma (AMM): Imaging Predictors of Progression for Patients Treated At UAMS
  Volume: 118 Page(s): 1691 - 1692
  11/18/2011 Authors: Heuck C; Sexton R; Dhodapkar M; Zhang Q; Usmani S; Nair B; van Rhee F; Hoering A; Crowley J; Shaughnessy JD
• Vesicle transfer and cell fusion: Emerging concepts of cell-cell communication in the tumor microenvironment.
  Volume: 12 Page(s): 159 - 164
  08/01/2011 Authors: Howcroft TK; Zhang H-G; Dhodapkar M; Mohla S
• Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
  Clin Immunol Volume: 140 Page(s): 160 - 166
  08/01/2011 Authors: Dhodapkar MV; Richter J
• Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
  Clin Cancer Res Volume: 17 Page(s): 3064 - 3076
  05/15/2011 Authors: Butterfield LH; Palucka AK; Britten CM; Dhodapkar MV; Hkansson L; Janetzki S; Kawakami Y; Kleen T-O; Lee PP; Maccalli C
• Spontaneous and therapy-induced immunity to pluripotency genes in humans: clinical implications, opportunities and challenges.
  Cancer Immunol Immunother Volume: 60 Page(s): 413 - 418
  03/01/2011 Authors: Dhodapkar MV; Dhodapkar KM
• Protein stress? pDCs go Toll-free.
  Blood Volume: 117 Page(s): 376 - 377
  01/13/2011 Authors: Dhodapkar MV
• Vaccines targeting cancer stem cells: are they within reach?
  Cancer J Volume: 17 Page(s): 397 - 402
  01/01/2011 Authors: Dhodapkar MV; Dhodapkar KM
• Predicting Disease Progression to Multiple Myeloma (MM) From MGUS/SMM In SWOG-0120 Observational Trial
  Volume: 116 Page(s): 803 - 804
  11/19/2010 Authors: Dhodapkar M; Shaughnessy J; Hoering A; Nair B; Bolejack V; van Rhee F; Crowley J; Barlogie B
• Early Development of CDX-1401, a Novel Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205, in Combination with Toll-Like Receptor (TLR) Agonists
  Volume: 33 Page(s): 895 - 896
  10/01/2010 Authors: Dhodapkar MV; Sznol M; Wang D; Chuang E; Carvajal R; Kluger H; Ramakrishna V; Vitale L; Davis T; Steinman RM
• Immune Microenvironment in Myeloma
  Volume: 47 Page(s): S265 - S265
  07/01/2010 Authors: Dhodapkar MV
• Natural immunity to pluripotency antigen OCT4 in humans.
  Proc Natl Acad Sci U S A Volume: 107 Page(s): 8718 - 8723
  05/11/2010 Authors: Dhodapkar KM; Feldman D; Matthews P; Radfar S; Pickering R; Turkula S; Zebroski H; Dhodapkar MV
• Immunity to stemness genes in human cancer.
  Curr Opin Immunol Volume: 22 Page(s): 245 - 250
  04/01/2010 Authors: Dhodapkar MV
• FC gamma R Mediated Regulation of Adaptive Immunity: Implications for Antibody Therapies
  Volume: 32 Page(s): 993 - 993
  11/01/2009 Authors: Dhodapkar M; Dhodapkar K
• Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.
  Blood Volume: 114 Page(s): 3413 - 3421
  10/15/2009 Authors: Kukreja A; Radfar S; Sun B-H; Insogna K; Dhodapkar MV
• Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
  Clin Adv Hematol Oncol Volume: 7 Page(s): 677 - 690
  10/01/2009 Authors: Neparidze N; Dhodapkar MV
• Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
  J Clin Oncol Volume: 27 Page(s): 4197 - 4203
  09/01/2009 Authors: Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD
• Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
  Ann N Y Acad Sci Volume: 1174 Page(s): 61 - 67
  09/01/2009 Authors: Neparidze N; Dhodapkar MV
• Role of teichoic acid choline moieties in the virulence of Streptococcus pneumoniae.
  Infect Immun Volume: 77 Page(s): 2824 - 2831
  07/01/2009 Authors: Gehre F; Spisek R; Kharat AS; Matthews P; Kukreja A; Anthony RM; Dhodapkar MV; Vollmer W; Tomasz A
• Myeloid neighborhood in myeloma: cancer's underbelly?
  Am J Hematol Volume: 84 Page(s): 395 - 396
  07/01/2009 Authors: Dhodapkar MV
• NKT cells in p53 deficiency.
  Blood Volume: 113 Page(s): 6268 - 6269
  06/18/2009 Authors: Dhodapkar MV; Neparidze N
• Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma
  Volume: 27
  05/20/2009 Authors: Dhodapkar MV; Bolejack V; Shaughnessy J; Matthews P; Pickering R; Qu P; Hoering A; Crowley J; Barlogie B
• International prognostic scoring system for Waldenstrom macroglobulinemia.
  Blood Volume: 113 Page(s): 4163 - 4170
  04/30/2009 Authors: Morel P; Duhamel A; Gobbi P; Dimopoulos MA; Dhodapkar MV; McCoy J; Crowley J; Ocio EM; Garcia-Sanz R; Treon SP
• Monoclonal antibodies for cancer immunotherapy.
  Lancet Volume: 373 Page(s): 1033 - 1040
  03/21/2009 Authors: Weiner LM; Dhodapkar MV; Ferrone S
• Inhibition of human dendritic cell activation by hydroethanolic but not lipophilic extracts of turmeric (Curcuma longa).
  Planta Med Volume: 75 Page(s): 312 - 315
  03/01/2009 Authors: Krasovsky J; Chang DH; Deng G; Yeung S; Lee M; Leung PC; Cunningham-Rundles S; Cassileth B; Dhodapkar MV
• Immune Microenvironment in Myeloma Pathobiology
  Volume: 9 Page(s): S21 - S22
  02/01/2009 Authors: Dhodapkar MV
• Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
  Blood Volume: 113 Page(s): 793 - 796
  01/22/2009 Authors: Dhodapkar MV; Hoering A; Gertz MA; Rivkin S; Szymonifka J; Crowley J; Barlogie B
• Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.
  Front Biosci (Landmark Ed) Volume: 14 Page(s): 796 - 807
  01/01/2009 Authors: Dhodapkar MV
• A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".
  J Transl Med Volume: 6 Page(s): 81
  12/23/2008 Authors: Butterfield LH; Disis ML; Fox BA; Lee PP; Khleif SN; Thurin M; Trinchieri G; Wang E; Wigginton J; Chaussabel D
• Role of chaperones and FcgammaR in immunogenic death.
  Curr Opin Immunol Volume: 20 Page(s): 512 - 517
  10/01/2008 Authors: Dhodapkar MV; Dhodapkar KM; Li Z
• Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.
  Blood Volume: 112 Page(s): 2878 - 2885
  10/01/2008 Authors: Dhodapkar KM; Barbuto S; Matthews P; Kukreja A; Mazumder A; Vesole D; Jagannath S; Dhodapkar MV
• Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.
  Blood Volume: 112 Page(s): 1308 - 1316
  08/15/2008 Authors: Chang DH; Deng H; Matthews P; Krasovsky J; Ragupathi G; Spisek R; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
• First thalidomide clinical trial in multiple myeloma: a decade.
  Blood Volume: 112 Page(s): 1035 - 1038
  08/15/2008 Authors: van Rhee F; Dhodapkar M; Shaughnessy JD; Anaissie E; Siegel D; Hoering A; Zeldis J; Jenkins B; Singhal S; Mehta J
• Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?
  Nat Clin Pract Oncol Volume: 5 Page(s): 372 - 373
  07/01/2008 Authors: Dhodapkar MV; Cooper DL
• Interactions of tumor cells with dendritic cells: balancing immunity and tolerance.
  Cell Death Differ Volume: 15 Page(s): 39 - 50
  01/01/2008 Authors: Dhodapkar MV; Dhodapkar KM; Palucka AK
• Immunobiology and Immunotherapy of Multiple Myeloma
  Page(s): 143 - 166
  01/01/2008 Authors: Dhodapkar MV
• Dendritic cells are specialized accessory cells along with TGF- for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3 precursors.
  Blood Volume: 110 Page(s): 4293 - 4302
  12/15/2007 Authors: Yamazaki S; Bonito AJ; Spisek R; Dhodapkar M; Inaba K; Steinman RM
• Gene expression profiles for prognosis in MGUS, coupled with signatures of oncogenic pathway deregulation provide a novel approach for selection of molecular targets in multiple myeloma
  Volume: 110 Page(s): 202A - 202A
  11/16/2007 Authors: Anguiano A; Acharya C; Satter K; McCluskey D; Gasperetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD
• Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
  Volume: 30 Page(s): 577 - 590
  09/01/2007 Authors: Atkins MB; Carbone D; Coukos G; Dhodapkar M; Ernstoff MS; Finke J; Gajewski TF; Gollob J; Lotze MT; Storkus W
• Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells.
  Cell Cycle Volume: 6 Page(s): 1962 - 1965
  08/15/2007 Authors: Spisek R; Dhodapkar MV
• Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program.
  J Exp Med Volume: 204 Page(s): 1359 - 1369
  06/11/2007 Authors: Dhodapkar KM; Banerjee D; Connolly J; Kukreja A; Matayeva E; Veri MC; Ravetch JV; Steinman RM; Dhodapkar MV
• Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
  Blood Volume: 109 Page(s): 4839 - 4845
  06/01/2007 Authors: Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
• International prognostic scoring system for Waldenstrom's macroglobulinemia
  Volume: 92 Page(s): 84 - 84
  06/01/2007 Authors: Morel P; Duhamel A; Gobbi P; Dimopoulos M; Dhodapkar M; Mccoy J; Ocio E; Garcia-Sanz R; Leblond V; Kyle R
• Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
  J Exp Med Volume: 204 Page(s): 831 - 840
  04/16/2007 Authors: Spisek R; Kukreja A; Chen L-C; Matthews P; Mazumder A; Vesole D; Jagannath S; Zebroski HA; Simpson AJG; Ritter G
• Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
  Blood Volume: 109 Page(s): 1692 - 1700
  02/15/2007 Authors: Zhan F; Barlogie B; Arzoumanian V; Huang Y; Williams DR; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M
• Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
  Br J Haematol Volume: 136 Page(s): 106 - 110
  01/01/2007 Authors: Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
• International prognostic scoring system (IPSS) for waldenstrom's macroglobulinemia (WM).
  Volume: 108 Page(s): 42A - 42A
  11/16/2006 Authors: Morel P; Duhamel A; Gobbi P; Dimopoulos M; Dhodapkar M; Mccoy J; Ocio E; Garcia-Sanz R; Treon S; Leblond V
• A gene expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.
  Volume: 108 Page(s): 969A - 969A
  11/16/2006 Authors: Zhan F; Barlogie B; Arzoumanian V; Huang Y; Hollmig K; Pineda-Roman M; Tricot G; van Rhee F; Zangari M; Dhodapkar M
• Induction of anti-tumor immunity by anti-tumor monoclonal antibodies
  Volume: 29 Page(s): 635 - 635
  11/01/2006 Authors: Dhodapkar MV
• Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients.
  Blood Volume: 108 Page(s): 2655 - 2661
  10/15/2006 Authors: Banerjee DK; Dhodapkar MV; Matayeva E; Steinman RM; Dhodapkar KM
• Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
  Cancer Immunol Immunother Volume: 55 Page(s): 1209 - 1218
  10/01/2006 Authors: Fay JW; Palucka AK; Paczesny S; Dhodapkar M; Johnston DA; Burkeholder S; Ueno H; Banchereau J
• Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
  Br J Haematol Volume: 135 Page(s): 158 - 164
  10/01/2006 Authors: Barlogie B; Tricot GJ; van Rhee F; Angtuaco E; Walker R; Epstein J; Shaughnessy JD; Jagannath S; Bolejack V; Gurley J
• Enhancement of clonogenicity of human multiple myeloma by dendritic cells.
  J Exp Med Volume: 203 Page(s): 1859 - 1865
  08/07/2006 Authors: Kukreja A; Hutchinson A; Dhodapkar K; Mazumder A; Vesole D; Angitapalli R; Jagannath S; Dhodapkar MV
• Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.
  Blood Volume: 108 Page(s): 618 - 621
  07/15/2006 Authors: Chang DH; Liu N; Klimek V; Hassoun H; Mazumder A; Nimer SD; Jagannath S; Dhodapkar MV
• Immunoprevention of cancer.
  Hematol Oncol Clin North Am Volume: 20 Page(s): 735 - 750
  06/01/2006 Authors: Spisek R; Dhodapkar MV
• Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
  Leukemia Volume: 20 Page(s): 345 - 349
  02/01/2006 Authors: Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
• Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
  Br J Haematol Volume: 132 Page(s): 155 - 161
  01/01/2006 Authors: Hassoun H; Reich L; Klimek VM; Dhodapkar M; Cohen A; Kewalramani T; Zimman R; Drake L; Riedel ER; Hedvat CV
• Immune response to premalignancy: insights from patients with monoclonal gammopathy.
  Ann N Y Acad Sci Volume: 1062 Page(s): 22 - 28
  12/01/2005 Authors: Dhodapkar MV
• Differential antigenic targets of anti-tumor immune response and selective immunity to stem cell associated group BSOX proteins in preneoplastic versus malignant gammopathy.
  Volume: 106 Page(s): 362B - 362B
  11/16/2005 Authors: Spisek R; Chen LC; Scanlan M; Simpson A; Ritter G; Rasmussen E; McCoy J; Murray A; Krasovsky J; Durie B
• Risk-adapted dosing of melphalan for systemic AL amyloidosis (AL) lowers treatment-related mortality: Early death but not post-3 month survival is linked to cardiac involvement.
  Volume: 106 Page(s): 337A - 337A
  11/16/2005 Authors: Comenzo RL; Zhou P; Hassoun H; Kewalramani T; Klimek V; Cohen AD; Ferrand SK; Dhodapkar M; Feldstein JT; Fleisher M
• The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for multiple myeloma.
  Volume: 106 Page(s): 972A - 972A
  11/16/2005 Authors: Hassoun H; Reich L; Klimek VM; Dhodapkar M; Cohen A; Kewalramani T; Riedel ER; Hedvat CV; Teruya-Feldstein J; Filippa DA
• Gene expression profiling of bulk CD138+plasma-cells in preneoplastic gammopathy/asymptomatic myeloma identifies distinct subsets of patients
  Volume: 106 Page(s): 355A - 355A
  11/16/2005 Authors: Dhodapkar MV; Zhan FH; Rasmussen E; Burington B; Durie B; Crowley J; Barlogie B; Shaughnessy J
• Extended survival and broad immune responses following vaccination of patients with metastatic melanoma with peptide-pulsed CD34+progenitor derived dendritic cells (DCs).
  Volume: 23 Page(s): 172S - 172S
  06/01/2005 Authors: Banchereau J; Palucka AK; Paczesny S; Dhodapkar M; Johnston D; Ueno H; Pineiro L; Burkeholder S; Fay J
• Prognostic factors add criteria to treat Waldenstrom's macroglobulinemia.
  Volume: 16 Page(s): 261 - 262
  06/01/2005 Authors: Morel P; Duhamel A; Dimopoulos M; San Miguel J; Barlogie B; Kyle R; Leblond V; Dhodapkar M; Mc Coy J; Treon S
• Recruiting dendritic cells to improve antibody therapy of cancer.
  Proc Natl Acad Sci U S A Volume: 102 Page(s): 6243 - 6244
  05/03/2005 Authors: Dhodapkar KM; Dhodapkar MV
• Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.
  J Exp Med Volume: 201 Page(s): 1503 - 1517
  05/02/2005 Authors: Chang DH; Osman K; Connolly J; Kukreja A; Krasovsky J; Pack M; Hutchinson A; Geller M; Liu N; Annable R
• Harnessing host immune responses to preneoplasia: promise and challenges.
  Cancer Immunol Immunother Volume: 54 Page(s): 409 - 413
  05/01/2005 Authors: Dhodapkar MV
• Spontaneous proliferation and type 2 cytokine secretion by CD4+T cells in patients with metastatic melanoma vaccinated with antigen-pulsed dendritic cells.
  J Clin Immunol Volume: 25 Page(s): 288 - 295
  05/01/2005 Authors: Palucka AK; Connolly J; Ueno H; Kohl J; Paczesny S; Dhodapkar M; Fay J; Banchereau J
• Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial.
  Bone Marrow Transplant Volume: 35 Page(s): 441 - 447
  03/01/2005 Authors: Gupta S; Zhou P; Hassoun H; Kewalramani T; Reich L; Costello S; Drake L; Klimek V; Dhodapkar M; Teruya-Feldstein J
• Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.
  Proc Natl Acad Sci U S A Volume: 102 Page(s): 2910 - 2915
  02/22/2005 Authors: Dhodapkar KM; Kaufman JL; Ehlers M; Banerjee DK; Bonvini E; Koenig S; Steinman RM; Ravetch JV; Dhodapkar MV
• Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma.
  J Immunother Volume: 28 Page(s): 158 - 168
  01/01/2005 Authors: Palucka AK; Dhodapkar MV; Paczesny S; Ueno H; Fay J; Banchereau J
• Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
  J Immunother Volume: 28 Page(s): 505 - 516
  01/01/2005 Authors: Banchereau J; Ueno H; Dhodapkar M; Connolly J; Finholt JP; Klechevsky E; Blanck J-P; Johnston DA; Palucka AK; Fay J
• Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628.
  Blood Volume: 104 Page(s): 3520 - 3526
  12/01/2004 Authors: Dhodapkar MV; Hussein MA; Rasmussen E; Solomon A; Larson RA; Crowley JJ; Barlogie B; United States Intergroup Trial Southwest Oncology Group
• Doxorubicin and dexamethasone followed by thalidomide and dexamethasone (AD-TD) as initial therapy for symptomatic patients with multiple myeloma
  Volume: 104 Page(s): 662A - 662A
  11/16/2004 Authors: Hassoun H; Reich L; Klimek VM; Kewalramani T; Dhodapkar M; Drake L; Zimman R; Hedvat CV; Teruya-Feldstein J; Fleisher M
• Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.
  Br J Haematol Volume: 124 Page(s): 309 - 314
  02/01/2004 Authors: Cohen AD; Zhou P; Xiao Q; Fleisher M; Kalakonda N; Akhurst T; Chitale DA; Moscowitz C; Dhodapkar MV; Teruya-Feldstein J
• Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
  J Exp Med Volume: 199 Page(s): 125 - 130
  01/05/2004 Authors: Lee E; Trepicchio WL; Oestreicher JL; Pittman D; Wang F; Chamian F; Dhodapkar M; Krueger JG
• Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.
  J Exp Med Volume: 198 Page(s): 1753 - 1757
  12/01/2003 Authors: Dhodapkar MV; Krasovsky J; Osman K; Geller MD
• Regression of metastatic melanoma by dendritic cell-induced T-cell immunity.
  Volume: 102 Page(s): 124A - 125A
  11/16/2003 Authors: Fay JW; Palucka K; Paczesny S; Dhodapkar M; Steinman R; Banchereau J
• Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma.
  Volume: 102 Page(s): 450A - 451A
  11/16/2003 Authors: Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M
• A phase II study of stem cell mobilization with IV melphalan (60 mg/M-2) + G-CSF in multiple myeloma.
  Volume: 102 Page(s): 956A - 956A
  11/16/2003 Authors: Gupta S; Costello S; Zhou P; Lilian R; Hani H; Klimek V; Kewalramani T; Dhodapkar M; Fleisher M; Hedvat C
• Systemic AL amyloidosis due to non-Hodgkin's lymphoma: An unusual clinicopathologic association.
  Volume: 102 Page(s): 279B - 279B
  11/16/2003 Authors: Cohen AD; Zhou P; Xiao QX; Fleisher M; Kalakonda N; Akhurst T; Chitale DA; Moskowitz C; Dhodapkar MV; Teruya-Feldstein J
• Dendritic cells as vectors and targets for therapy
  Volume: 121 Page(s): 1235 - 1235
  11/01/2003 Authors: Banchereau J; Jego G; Paczesny S; Fay JW; Dhodapkar M; Steinman R; Pascual V; Palucka AK
• Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.
  Br J Haematol Volume: 122 Page(s): 617 - 622
  08/01/2003 Authors: Fujii S-I; Shimizu K; Klimek V; Geller MD; Nimer SD; Dhodapkar MV
• Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.
  Cancer Immun Volume: 3 Page(s): 9
  07/23/2003 Authors: Dhodapkar MV; Osman K; Teruya-Feldstein J; Filippa D; Hedvat CV; Iversen K; Kolb D; Geller MD; Hassoun H; Kewalramani T
• A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.
  J Exp Med Volume: 197 Page(s): 1667 - 1676
  06/16/2003 Authors: Dhodapkar MV; Geller MD; Chang DH; Shimizu K; Fujii S-I; Dhodapkar KM; Krasovsky J
• Dendritic cells and immunotherapy for cancer.
  Int J Hematol Volume: 77 Page(s): 439 - 443
  06/01/2003 Authors: Chang DH; Dhodapkar MV
• Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
  Volume: 30 Page(s): 116 - 120
  04/01/2003 Authors: Kyle RA; Treon SP; Alexanian R; Barlogie B; Bjrkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M
• Dendritic cell function in vivo during the steady state: a role in peripheral tolerance.
  Volume: 987 Page(s): 15 - 25
  04/01/2003 Authors: Steinman RM; Hawiger D; Liu K; Bonifaz L; Bonnyay D; Mahnke K; Iyoda T; Ravetch J; Dhodapkar M; Inaba K
• Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
  Semin Oncol Volume: 30 Page(s): 220 - 225
  04/01/2003 Authors: Dhodapkar MV; Jacobson JL; Gertz MA; Crowley JJ; Barlogie B
• Dendritic cell-mediated immunization in macroglobulinemia.
  Semin Oncol Volume: 30 Page(s): 305 - 308
  04/01/2003 Authors: Dhodapkar MV
• Dendritic cells as melanoma vaccines
  Volume: 51 Page(s): S385 - S386
  03/01/2003 Authors: Palucka AK; Paczesny S; Dhodapkar MV; Steinman RM; Fay JW; Banchereau J
• Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells.
  J Immunol Methods Volume: 272 Page(s): 147 - 159
  01/15/2003 Authors: Fujii S-I; Shimizu K; Steinman RM; Dhodapkar MV
• Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
  J Immunother Volume: 26 Page(s): 432 - 439
  01/01/2003 Authors: Palucka AK; Dhodapkar MV; Paczesny S; Burkeholder S; Wittkowski KM; Steinman RM; Fay J; Banchereau J
• Fludarabine for Waldenstrom's macroglobulinemia: Update of Southwest Oncology Intergroup 59003 trial.
  Volume: 100 Page(s): 396A - 397A
  11/16/2002 Authors: Fassas A; Dhodapkar M; Barlogie B; Jacobson J; Kyle R; Roodman D; Crowley J
• Results of autologous stem cell transplantation (SCT) following stem cell mobilization with melphalan in myeloma patients.
  Volume: 100 Page(s): 435A - 435A
  11/16/2002 Authors: Comenzo RL; Costello S; Reich L; Drake L; Ping Z; Martinez C; Klimek V; Kewalramani T; Osman K; Dhodapkar M
• T cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor-loaded dendritic cells.
  Volume: 100 Page(s): 170A - 171A
  11/16/2002 Authors: Dhodapkar MV; Krasovsky J; Olson K
• T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.
  Proc Natl Acad Sci U S A Volume: 99 Page(s): 13009 - 13013
  10/01/2002 Authors: Dhodapkar MV; Krasovsky J; Olson K
• Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.
  Blood Volume: 100 Page(s): 174 - 177
  07/01/2002 Authors: Dhodapkar MV; Steinman RM
• The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.
  Blood Volume: 99 Page(s): 2929 - 2939
  04/15/2002 Authors: Berger CL; Hanlon D; Kanada D; Dhodapkar M; Lombillo V; Wang N; Christensen I; Howe G; Crouch J; El-Fishawy P
• Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
  J Exp Med Volume: 195 Page(s): 125 - 133
  01/07/2002 Authors: Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
• Blood stem cell mobilization with intravenous melphalan in patients with multiple myeloma.
  Volume: 98 Page(s): 180A - 180A
  11/16/2001 Authors: Osman K; Drake L; Costello S; Reich L; Wuest D; Klimek V; Kewalramani T; Gucciardo A; Fleisher M; Martinez C
• Anti-tumor monoclonal antibodies enhance cross presentation of cellular antigens and generation of tumor specific killer cells by dendritic cells.
  Volume: 98 Page(s): 33B - 33B
  11/16/2001 Authors: Dhodapkar KM; Krasovsky J; Williamson B; Dhodapkar MV
• Active immunization against cancer with dendritic cells: the near future.
  Int J Cancer Volume: 94 Page(s): 459 - 473
  11/01/2001 Authors: Steinman RM; Dhodapkar M
• Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
  Mod Pathol Volume: 14 Page(s): 1052 - 1058
  10/01/2001 Authors: Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
  Cancer Res Volume: 61 Page(s): 6451 - 6458
  09/01/2001 Authors: Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N
• Prognostic factors and response to fludarabine therapy in patients with Waldenstrm macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
  Blood Volume: 98 Page(s): 41 - 48
  07/01/2001 Authors: Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
• Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.
  J Exp Med Volume: 193 Page(s): 233 - 238
  01/15/2001 Authors: Dhodapkar MV; Steinman RM; Krasovsky J; Munz C; Bhardwaj N
• Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
  Clin Cancer Res Volume: 6 Page(s): 4831 - 4838
  12/01/2000 Authors: Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
• Dendritic cell immunotherapy of metastatic melanoma using CD34(+) hematopoietic progenitor-derived dendritic cells (CD34-DC) induced immune responses to melanoma antigen and resulted in clinical regression of metastatic disease.
  Volume: 96 Page(s): 807A - 807A
  11/16/2000 Authors: Fay J; Palucka K; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Bhardwaj N; Pineiro L; Stone M; Steinman R
• Waldenstrm's macroglobulinemia.
  Curr Treat Options Oncol Volume: 1 Page(s): 97 - 103
  06/01/2000 Authors: Desikan KR; Dhodapkar MV; Barlogie B
• Active immunization of humans with dendritic cells.
  J Clin Immunol Volume: 20 Page(s): 167 - 174
  05/01/2000 Authors: Dhodapkar MV; Bhardwaj N
• Dendritic cells derived from CD34+hematopoietic progenitors induce primary and secondary immune responses in patients with stage IV melanoma.
  Volume: 14 Page(s): A944 - A944
  04/20/2000 Authors: Palucka K; Fay J; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Bhardwaj N; Stone M; Piniero L; Steinman R
• Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes.
  J Clin Invest Volume: 105 Page(s): R9 - R14
  03/01/2000 Authors: Dhodapkar MV; Krasovsky J; Steinman RM; Bhardwaj N
• Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
  Bone Marrow Transplant Volume: 25 Page(s): 483 - 487
  03/01/2000 Authors: Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D
• Antitumor activity of thalidomide in refractory multiple myeloma.
  N Engl J Med Volume: 341 Page(s): 1565 - 1571
  11/18/1999 Authors: Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M
• Human CD8+T cell immunity following mature dendritic cell injection is durable and can be boosted without need for helper epitopes.
  Volume: 94 Page(s): 678A - 678A
  11/15/1999 Authors: Dhodapkar MV; Steinman RM; Bhardwaj N
• Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with Waldenstrom's macroglobulinemia (WM).
  Volume: 94 Page(s): 705A - 705A
  11/15/1999 Authors: Dhodapkar MV; Jacobson J; Gertz M; Rivkin SE; Weiss GR; Gandara DR; Chapman RA; Crowley J; Salmon S; Kyle R
• Syndecan-1 (CD138) expression in multiple myeloma: Immunohistochemical and flow cytometric analysis in bone marrow specimens
  Volume: 112 Page(s): 563 - 564
  10/01/1999 Authors: Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
• Rapid generation of broad T cell immunity in humans following a single injection of mature dendritic cells.
  Volume: 42 Page(s): S382 - S382
  09/01/1999 Authors: Dhodapkar MV; Steinman RM; Sapp M; Desai H; Fosella C; Krasovsky J; Donahue SM; Dunbar PR; Cerundolo V; Nixon DF
• Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.
  J Clin Invest Volume: 104 Page(s): 173 - 180
  07/01/1999 Authors: Dhodapkar MV; Steinman RM; Sapp M; Desai H; Fossella C; Krasovsky J; Donahoe SM; Dunbar PR; Cerundolo V; Nixon DF
• Recent advances in the treatment of multiple myeloma.
  Curr Opin Hematol Volume: 6 Page(s): 216 - 221
  07/01/1999 Authors: Desikan KR; Dhodapkar MV; Munshi NC; Barlogie B
• Syndecan-1 (CD 138) in myeloma and lymphoid malignancies: a multifunctional regulator of cell behavior within the tumor microenvironment.
  Leuk Lymphoma Volume: 34 Page(s): 35 - 43
  06/01/1999 Authors: Dhodapkar MV; Sanderson RD
• High-dose therapy with autologous haemopoietic stem cell support for Waldenstrm's macroglobulinaemia.
  Br J Haematol Volume: 105 Page(s): 993 - 996
  06/01/1999 Authors: Desikan R; Dhodapkar M; Siegel D; Fassas A; Singh J; Singhal S; Mehta J; Vesole D; Tricot G; Jagannath S
• Biologic and therapeutic determinants of bone mineral density in multiple myeloma.
  Leuk Lymphoma Volume: 32 Page(s): 121 - 127
  12/01/1998 Authors: Dhodapkar MV; Weinstein R; Tricot G; Jagannath S; Parfitt AM; Manolagas SC; Barlogie B
• High dose therapy with autologous peripheral blood stem cell (PBSC) support for Waldenstrom's Macroglobulinemia: A pilot study.
  Volume: 92 Page(s): 660A - 660A
  11/15/1998 Authors: Desikan R; Dhodapkar M; Siegel D; Fassas A; Singh J; Singhal S; Mehta J; Vesole D; Tricot G; Jagannath S
• Anti-myeloma activity of pamidronate in vivo.
  Br J Haematol Volume: 103 Page(s): 530 - 532
  11/01/1998 Authors: Dhodapkar MV; Singh J; Mehta J; Fassas A; Desikan KR; Perlman M; Munshi NC; Barlogie B
• Nervous system dysfunction in Waldenstrm's macroglobulinemia: response to treatment.
  Neurology Volume: 51 Page(s): 1210 - 1213
  10/01/1998 Authors: Rudnicki SA; Harik SI; Dhodapkar M; Barlogie B; Eidelberg D
• Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with myeloma (vol 99, pg 368, 1997)
  BRITISH JOURNAL OF HAEMATOLOGY Volume: 101 Page(s): 398 - 398
  05/01/1998 Authors: Dhodapkar MV; Kelly T; Theus A; Athota AB; Barlogie B; Sanderson RD
• Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
  Blood Volume: 91 Page(s): 2679 - 2688
  04/15/1998 Authors: Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
• The systemic amyloidoses.
  N Engl J Med Volume: 338 Page(s): 264
  01/22/1998 Authors: Dhodapkar M; Barlogie B; Gertz M
• The systemic amyloidoses.
  N Engl J Med Volume: 338 Page(s): 264
  01/22/1998 Authors: Mahmoud S
• Phase II intergroup trial of fludarabine (FAMP) in Waldenstrom's macroglobulinemia (WM): Results of Southwest Oncology Group trial (SWOG 9003) in 220 patients.
  Volume: 90 Page(s): 2571 - 2571
  11/15/1997 Authors: Dhodapkar M; Jacobson J; Gertz M; Crowley J; Shurafa M; Salmon S; Kyle R; Barlogie B
• Syndecan-1 is a key multifunctional regulator of myeloma pathobiology.
  Volume: 90 Page(s): 2618 - 2618
  11/15/1997 Authors: Dhodapkar M; Abe E; Lacy M; Theus A; Langford K; Barlogie B; Sanderson R
• Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.
  Br J Haematol Volume: 99 Page(s): 368 - 371
  11/01/1997 Authors: Dhodapkar MV; Kelly T; Theus A; Athota AB; Barlogie B; Sanderson RD
• Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
  Leuk Lymphoma Volume: 27 Page(s): 315 - 319
  10/01/1997 Authors: Desikan KR; Dhodapkar MV; Hough A; Waldron T; Jagannath S; Siegel D; Barlogie B; Tricot G
• Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.
  Leuk Lymphoma Volume: 27 Page(s): 351 - 356
  10/01/1997 Authors: Dhodapkar MV; Jagannath S; Vesole D; Munshi N; Naucke S; Tricot G; Barlogie B
• Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
  Clin Cancer Res Volume: 3 Page(s): 1093 - 1100
  07/01/1997 Authors: Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
• Biology and therapy of immunoglobulin deposition diseases.
  Hematol Oncol Clin North Am Volume: 11 Page(s): 89 - 110
  02/01/1997 Authors: Dhodapkar MV; Merlini G; Solomon A
• Shed syndecan-1 inhibits myeloma cell growth: A mechanism of autocrine growth control in multiple myeloma.
  Volume: 88 Page(s): 395 - 395
  11/15/1996 Authors: Dhodapkar M; Theus A; Langford K; Butch A; Barlogie B; Sanderson R
• Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
  Cancer Volume: 77 Page(s): 683 - 690
  02/15/1996 Authors: Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
• Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen - An analysis of patients entered on four prospective clinical trials
  CANCER Volume: 77 Page(s): 683 - 690
  02/15/1996 Authors: Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
• Evidence of systemic bone disease (ED) in patients with multiple myeloma (MM): Biologic and therapeutic determinants of changes in bone density?
  Volume: 86 Page(s): 739 - 739
  11/15/1995 Authors: Dhodapkar M; Weinstein R; Jagannath S; Tricot G; Vaught L; Manolagas S; Barlogie B
• Anti-IL-6 monoclonal antibody (BE-8) and suramin for treatment of Castleman's disease (CD)
  Volume: 86 Page(s): 745 - 745
  11/15/1995 Authors: Munshi NC; Wijdenes J; Fassas A; Vesole D; Jagannath SJ; Cheson B; Butch A; Dhodapkar M; Tricot G; Barlogie B
• Prognostic factors identifying myeloma-related mortality within 6 months (MRM-6M) after autotransplantation (AT) in multiple myeloma (MM).
  Volume: 86 Page(s): 819 - 819
  11/15/1995 Authors: Siegel D; Dhodapkar M; Tricot G; Jagannath S; Vesole D; Flick J; Desikan K; Vaught L; Barlogie B
• Efficacy of pulse dexamethasone (DEX) plus maintenance alpha interferon (IFN) in primary systemic amyloidosis (AL).
  Volume: 86 Page(s): 1756 - 1756
  11/15/1995 Authors: Dhodapkar M; Jagannath S; Vesole D; Tricot G; Munshi N; Naucke S; Barlogie B
• Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes.
  Leuk Res Volume: 19 Page(s): 719 - 726
  10/01/1995 Authors: Dhodapkar M; Grill J; Lust JA
• Estrogen replacement therapy withdrawal and regression of metastatic breast cancer.
  Cancer Volume: 75 Page(s): 43 - 46
  01/01/1995 Authors: Dhodapkar MV; Ingle JN; Ahmann DL
• ESTROGEN REPLACEMENT THERAPY WITHDRAWAL AND REGRESSION OF METASTATIC BREAST-CANCER
  CANCER Volume: 75 Page(s): 43 - 46
  01/01/1995 Authors: DHODAPKAR MV; INGLE JN; AHMANN DL
• Regular use of a verbal pain scale improves the understanding of oncology inpatient pain intensity.
  J Clin Oncol Volume: 12 Page(s): 2751 - 2755
  12/01/1994 Authors: Au E; Loprinzi CL; Dhodapkar M; Nelson T; Novotny P; Hammack J; O'Fallon J
• T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: response to immunosuppressive therapy.
  Mayo Clin Proc Volume: 69 Page(s): 1085 - 1088
  11/01/1994 Authors: Dhodapkar MV; Lust JA; Phyliky RL
• Chronic natural killer cell lymphocytosis: a descriptive clinical study.
  Blood Volume: 84 Page(s): 2721 - 2725
  10/15/1994 Authors: Tefferi A; Li CY; Witzig TE; Dhodapkar MV; Okuno SH; Phyliky RL
• Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
  Blood Volume: 84 Page(s): 1620 - 1627
  09/01/1994 Authors: Dhodapkar MV; Li CY; Lust JA; Tefferi A; Phyliky RL
• Reversible encephalopathy after cryopreserved peripheral blood stem cell infusion.
  Am J Hematol Volume: 45 Page(s): 187 - 188
  02/01/1994 Authors: Dhodapkar M; Goldberg SL; Tefferi A; Gertz MA
• Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.
  Invest New Drugs Volume: 12 Page(s): 207 - 216
  01/01/1994 Authors: Dhodapkar MV; Richardson RL; Reid JM; Ames MM
• CLINICAL SPECTRUM OF CD3 (+) CLONAL LARGE GRANULAR LYMPHOCYTE (LGL) PROLIFERATIONS
  Volume: 82 Page(s): A132 - A132
  11/15/1993 Authors: DHODAPKAR MV; LI CY; LUST JA; TEFFERI AT; PHYLIKY RL
• PROGNOSTIC-SIGNIFICANCE OF ABNORMAL REGIONAL HYPERMETHYLATION OF THE CALCITONIN-GENE IN PRIMARY MYELODYSPLASTIC SYNDROMES
  Volume: 82 Page(s): A552 - A552
  11/15/1993 Authors: DHODAPKAR MV; GRILL JP; LUST JA
• HYPERMETHYLATION OF THE CALCITONIN-GENE AS A MARKER FOR CLONALITY IN MYELODYSPLASTIC SYNDROMES
  Volume: 21 Page(s): 1047 - 1047
  08/01/1993 Authors: DHODAPKAR MV; THIBODEAU SN; LUST JA
• Prognostic features and survival in young adults with early/intermediate chronic lymphocytic leukemia (B-CLL): a single institution study.
  Leukemia Volume: 7 Page(s): 1232 - 1235
  08/01/1993 Authors: Dhodapkar M; Tefferi A; Su J; Phyliky RL
• Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma.
  Cancer Volume: 72 Page(s): 108 - 113
  07/01/1993 Authors: Witzig TE; Dhodapkar MV; Kyle RA; Greipp PR
• Hemorrhagic pleural effusion and pleural thickening as a complication of chronic lymphocytic leukemia.
  Am J Hematol Volume: 42 Page(s): 221 - 224
  02/01/1993 Authors: Dhodapkar M; Yale SH; Hoagland HC